These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
57 related articles for article (PubMed ID: 18083510)
1. Characterization of HSD17B1 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer. Plourde M; Samson C; Durocher F; Sinilnokova O; Simard J; J Steroid Biochem Mol Biol; 2008 Mar; 109(1-2):115-28. PubMed ID: 18083510 [TBL] [Abstract][Full Text] [Related]
2. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families. Durocher F; Labrie Y; Soucy P; Sinilnikova O; Labuda D; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Ouellette G; Pichette R; Plante M; Tavtigian SV; Simard J BMC Cancer; 2006 Sep; 6():230. PubMed ID: 17010193 [TBL] [Abstract][Full Text] [Related]
3. Mutation analysis and characterization of HSD17B2 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer. Plourde M; Manhes C; Leblanc G; Durocher F; Dumont M; Sinilnikova O; ; Simard J J Mol Endocrinol; 2008 Apr; 40(4):161-72. PubMed ID: 18372405 [TBL] [Abstract][Full Text] [Related]
4. Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer. Plourde M; Ferland A; Soucy P; Hamdi Y; Tranchant M; Durocher F; Sinilnikova O; Luu The V; ; Simard J J Steroid Biochem Mol Biol; 2009 Sep; 116(3-5):134-53. PubMed ID: 19460435 [TBL] [Abstract][Full Text] [Related]
5. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada]. Tonin PN Bull Cancer; 2006 Sep; 93(9):841-6. PubMed ID: 16980226 [TBL] [Abstract][Full Text] [Related]
6. Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohort studies. Feigelson HS; Cox DG; Cann HM; Wacholder S; Kaaks R; Henderson BE; Albanes D; Altshuler D; Berglund G; Berrino F; Bingham S; Buring JE; Burtt NP; Calle EE; Chanock SJ; Clavel-Chapelon F; Colditz G; Diver WR; Freedman ML; Haiman CA; Hankinson SE; Hayes RB; Hirschhorn JN; Hunter D; Kolonel LN; Kraft P; LeMarchand L; Linseisen J; Modi W; Navarro C; Peeters PH; Pike MC; Riboli E; Setiawan VW; Stram DO; Thomas G; Thun MJ; Tjonneland A; Trichopoulos D Cancer Res; 2006 Feb; 66(4):2468-75. PubMed ID: 16489054 [TBL] [Abstract][Full Text] [Related]
7. Analysis of ZNF350/ZBRK1 promoter variants and breast cancer susceptibility in non-BRCA1/2 French Canadian breast cancer families. Plourde KV; Labrie Y; Desjardins S; Belleau P; Ouellette G; Durocher F; J Hum Genet; 2013 Feb; 58(2):59-66. PubMed ID: 23151675 [TBL] [Abstract][Full Text] [Related]
8. Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families. Oros KK; Leblanc G; Arcand SL; Shen Z; Perret C; Mes-Masson AM; Foulkes WD; Ghadirian P; Provencher D; Tonin PN BMC Med Genet; 2006 Mar; 7():23. PubMed ID: 16539696 [TBL] [Abstract][Full Text] [Related]
9. Genetic sequence variations of BRCA1-interacting genes AURKA, BAP1, BARD1 and DHX9 in French Canadian families with high risk of breast cancer. Guénard F; Labrie Y; Ouellette G; Beauparlant CJ; Durocher F; J Hum Genet; 2009 Mar; 54(3):152-61. PubMed ID: 19197335 [TBL] [Abstract][Full Text] [Related]
10. Genetic variants and haplotype analyses of the ZBRK1/ZNF350 gene in high-risk non BRCA1/2 French Canadian breast and ovarian cancer families. Desjardins S; Belleau P; Labrie Y; Ouellette G; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Pichette R; Plante M; ; Durocher F Int J Cancer; 2008 Jan; 122(1):108-16. PubMed ID: 17764113 [TBL] [Abstract][Full Text] [Related]
11. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals. Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252 [TBL] [Abstract][Full Text] [Related]
12. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Antoniou AC; Durocher F; Smith P; Simard J; Easton DF; Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652 [TBL] [Abstract][Full Text] [Related]
13. [Germline mutation of BRCA1 gene in Polish families with strong aggregation of breast and/or ovarian cancer based on coding sequence analysis using the SSCP method]. Byrski T Ann Acad Med Stetin; 2003; 49():27-43. PubMed ID: 15552838 [TBL] [Abstract][Full Text] [Related]
14. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Simard J; Tonin P; Durocher F; Morgan K; Rommens J; Gingras S; Samson C; Leblanc JF; Bélanger C; Dion F Nat Genet; 1994 Dec; 8(4):392-8. PubMed ID: 7894492 [TBL] [Abstract][Full Text] [Related]
15. Analysis of GADD45A sequence variations in French Canadian families with high risk of breast cancer. Desjardins S; Ouellette G; Labrie Y; Simard J; ; Durocher F J Hum Genet; 2008; 53(6):490-498. PubMed ID: 18350249 [TBL] [Abstract][Full Text] [Related]
16. Mutation analysis of the BCCIP gene for breast cancer susceptibility in breast/ovarian cancer families. Bonache S; Gutierrez-Enriquez S; Tenés A; Masas M; Balmaña J; Diez O Gynecol Oncol; 2013 Nov; 131(2):460-3. PubMed ID: 23911796 [TBL] [Abstract][Full Text] [Related]
17. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives. Egeli U; Cecener G; Tunca B; Tasdelen I Cancer Invest; 2006; 24(5):484-91. PubMed ID: 16939956 [TBL] [Abstract][Full Text] [Related]
18. Genetic variation in the HSD17B1 gene and risk of prostate cancer. Kraft P; Pharoah P; Chanock SJ; Albanes D; Kolonel LN; Hayes RB; Altshuler D; Andriole G; Berg C; Boeing H; Burtt NP; Bueno-de-Mesquita B; Calle EE; Cann H; Canzian F; Chen YC; Crawford DE; Dunning AM; Feigelson HS; Freedman ML; Gaziano JM; Giovannucci E; Gonzalez CA; Haiman CA; Hallmans G; Henderson BE; Hirschhorn JN; Hunter DJ; Kaaks R; Key T; Le Marchand L; Ma J; Overvad K; Palli D; Pike MC; Riboli E; Rodriguez C; Setiawan WV; Stampfer MJ; Stram DO; Thomas G; Thun MJ; Travis R; Trichopoulou A; Virtamo J; Wacholder S PLoS Genet; 2005 Nov; 1(5):e68. PubMed ID: 16311626 [TBL] [Abstract][Full Text] [Related]
19. Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene. Ticha I; Kleibl Z; Stribrna J; Kotlas J; Zimovjanova M; Mateju M; Zikan M; Pohlreich P Breast Cancer Res Treat; 2010 Nov; 124(2):337-47. PubMed ID: 20135348 [TBL] [Abstract][Full Text] [Related]
20. Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer. Merajver SD; Frank TS; Xu J; Pham TM; Calzone KA; Bennett-Baker P; Chamberlain J; Boyd J; Garber JE; Collins FS Clin Cancer Res; 1995 May; 1(5):539-44. PubMed ID: 9816013 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]